Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CYT - Cyteir Therapeutics, Inc.
Market Cap 96.95M P/E - EPS this Y - Ern Qtrly Grth -
Income -33.22M Forward P/E -2.26 EPS next Y - 50D Avg Chg 14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 46.00%
Dividend N/A Price/Book 0.72 EPS next 5Y 42.90% 52W High Chg -3.00%
Recommedations 3.00 Quick Ratio 21.66 Shares Outstanding 36M 52W Low Chg 142.00%
Insider Own 6.64% ROA -14.50% Shares Float 10.83M Beta 0.10
Inst Own 76.83% ROE -23.81% Shares Shorted/Prior 319.73K/345.80K Price 2.73
Gross Margin - Profit Margin - Avg. Volume 289,238 Target Price 3.00
Oper. Margin - Earnings Date - Volume 356,901 Change 0.00%
Healthcare | Biotechnology | United States
About Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Cyteir Therapeutics, Inc. News
03/07/24 Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
10/12/23 Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
06/30/23 Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
06/03/23 Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
05/10/23 Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
04/20/23 Insiders who bought Cyteir Therapeutics, Inc. (NASDAQ:CYT) last year must be regretting not buying more as market cap hits US$72m
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Novo Holdings A/S 10% Owner 10% Owner Jul 19 Sell 2.76 101,900 281,244 3,522,136 07/20/23
Novo Holdings A/S 10% Owner 10% Owner Jul 14 Sell 2.75 38,600 106,150 3,624,036 07/18/23
Novo Holdings A/S 10% Owner 10% Owner Jun 30 Sell 2.6341 200,937 529,288 3,662,636 07/03/23
Novo Holdings A/S 10% Owner 10% Owner Jun 26 Sell 1.78 40,415 71,939 3,863,573 06/28/23
Novo Holdings A/S 10% Owner 10% Owner Jun 21 Sell 1.94 13,298 25,798 3,903,988 06/23/23
Novo Holdings A/S 10% Owner 10% Owner Jun 15 Sell 2.06 16,729 34,462 3,917,286 06/20/23
Novo Holdings A/S 10% Owner 10% Owner Jun 12 Sell 2.09 6,398 13,372 3,934,015 06/14/23
RENSCHLER MARKUS MD President and CEO President and CEO Dec 21 Option 1.12 136,782 153,196 978,736 12/23/22
Zakrzewski Joseph S Director Director Dec 07 Buy 1.30 21,202 27,563 154,618 12/08/22
Novo Holdings A/S 10% Owner 10% Owner Jul 20 Sell 3.00 900,000 2,700,000 3,940,413 07/22/22
Zakrzewski Joseph S Director Director May 10 Buy 1.8 50,406 90,731 132,673 05/12/22
Zakrzewski Joseph S Director Director Dec 23 Buy 9.97 1,100 10,967 82,267 12/28/21